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Abstract
Background—Experts have called for the inclusion of values clarification (VC) exercises in
decision aids (DA) as a means of improving their effectiveness, but little research has examined
the effects of such exercises.
Objective—To determine whether adding a VC exercise to a DA on heart disease prevention
improves decision making outcomes.
Design—Randomized trial.
Setting—UNC Decision Support Laboratory.
Patients—Adults ages 40–80 with no history of cardiovascular disease.
Intervention—A web-based heart disease prevention DA with or without a VC exercise.
Measurements—Pre and post-intervention decisional conflict and intent to reduce CHD risk.
Post-intervention self-efficacy and perceived values concordance.
Results—We enrolled 137 participants (62 in DA; 75 in VC) with moderate decisional conflict
(DA 2.4; VC 2.5) and no baseline differences among groups. After the interventions, we found no
clinically or statistically significant differences between groups in decisional conflict (DA 1.8; VC
1.9; absolute difference VC-DA 0.1, 95% CI −0.1 to 0.3), intent to reduce CHD risk (DA 98%;
VC 100%; absolute differences VC-DA: 2%, 95% CI −0.02% to 5%), perceived values
concordance (DA 95%, VC 92%; absolute difference VC-DA −3%, 95% CI −11 to +5%), or self
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efficacy for risk reduction (DA 97%, VC 92%; absolute difference VC-DA −5%, 95% CI −13 to
+3%). However, VC tended to change some decisions about risk reduction strategies.
Limitations—Use of a hypothetical scenario. Ceiling effects for some outcomes.
Conclusions—Adding a VC intervention to a DA did not further improve decision making
outcomes in a population of highly educated and motivated adults responding to scenario-based
questions. Work is needed to determine the effects of VC on more diverse populations and more
distal outcomes.
Introduction
Decision aids have been widely recommended as an adjunct to decision making for
healthcare decisions with clinical equipoise.1,2 In this setting, decision aids help individuals
learn about healthcare options, clarify their values, and make decisions about their health.
The benefits of decision aids, which have been enumerated in several systematic evidence
reviews,3,4 include improved patient knowledge, improved expectations about the benefits
and harms associated with a decision, reduced conflict from feeling uninformed, increased
participation in decision making, reduced indecision, and reduced conflict from unclear
values.
With preliminary evidence for effectiveness of decision aids in clarifying values, the
International Panel for Decision Aid Standards5 recommended that every decision aid
include some form of values clarification. Values clarification (VC) is a process by which
people form and communicate the relative desirability of decision options and their features.
Most decision aids to date allow individuals to implicitly consider their values by learning
about the pros and cons of decision options.6 However, values clarification can be done in
more explicit ways. Examples include ranking and rating different features of decision
options to facilitate a decision (ranking and rating), and viewing others engaged in decision
making and identifying one’s own similarity to the values of individuals making those
choices (social matching). The effect of adding such explicit values clarification exercises to
decision aids is unclear with evidence limited to a few studies, which used different methods
and achieved mixed results.4,6
We previously developed a decision aid on heart disease prevention called Heart to Heart.7
This decision aid encouraged CHD prevention and facilitated a choice among equally
effective options for CHD risk reduction. In testing, this decision aid was effective in
increasing intent for CHD risk reduction.8 Like most decision aids, however, it did not
include an explicit values clarification exercise.
An explicit values clarification exercise might be a useful addition to a CHD prevention
decision aid because pilot work suggests that individuals value the attributes of CHD
prevention options differently 9 and that a majority of individuals have difficulty
determining the best way to reduce their CHD risk.8 Therefore, in this study, we sought to
determine whether adding an explicit values clarification exercise to our decision aid on
heart disease prevention improved decision making outcomes, including decisional conflict,
intent for screening, perceived value concordance, and self-efficacy.
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We performed a randomized trial examining the effect of adding a values clarification
exercise to a decision aid on heart disease prevention. An overview of the study design is
shown in Figure 1. The study was conducted in the UNC Decision Support Laboratory and
was approved by UNC’s Institutional Review Board with each participant providing
informed consent prior to participation.
Study participants
For our study, we recruited a convenience sample of men and women from a registry of
participants interested in decision support testing. Individuals in this registry had previously
responded to mass information emails, television commercials, print media, and word of
mouth with their interest and are routinely invited to opt into studies for which they are
eligible.
For this study, we sent emailed or mailed invitations to registry participants who were ages
45–80, had no prior history of cardiovascular disease, and had no prior participation in
studies about CHD prevention (n~300). We then called registry participants who indicated
initial interest to confirm their eligibility. During these phone calls, we asked individuals
their age and gender and included individuals (men 45 and older and women age 55 and
older) who were likely to be at moderate to high risk of heart disease when considering risk
factor information that we provided as part of a hypothetical scenario in our study (described
below).
Hypothetical Scenario
To ensure that each participant was at moderate to high risk and had treatment options for
the primary prevention of CHD to consider, we provided all participants with a hypothetical
scenario. This scenario asked participants to imagine a visit with their doctor in which they
were told they had elevated blood pressure (160/99 mmHg) and high cholesterol (total 230
mg/dl and HDL of 35 mg/dl), making them at overall moderate (6–10%) to high risk (>10%)
based on population estimates for people of their own age decade and gender.10 Participants
then combined this hypothetical information with their own age, gender, smoking status, and
diabetes status to navigate the decision aid (and, if assigned, values clarification exercise).
Randomization
We used a computerized random-number generator to assign participants to our decision aid
alone (DA) or our decision aid in combination with an explicit values clarification exercise
(DA + VC). Random assignments were sealed in security envelopes until after baseline
survey administration. The research assistant then opened the seal on the security envelope,
determined the assignment, and helped the subject access the appropriate intervention.
The Interventions
We had all participants view the Heart to Heart decision aid (available at www.med-
decisions.com). This decision aid helps individuals with no prior history of heart disease
make decisions about how to lower their future likelihood of CHD events. It calculates an
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individual’s overall risk of CHD events in the next 10 years using a continuous Framingham
risk equation11 and presents this risk in both numerical and graphical formats. The decision
aid then shows patients a list of up to four evidence-based treatment options for risk
reduction (aspirin, blood pressure medicine, cholesterol medicine, and/or smoking
cessation), a list of pros and cons of each option (including the benefit for heart disease,
benefit for other medical conditions, side effects, degree of difficulty for most people, and
cost), a presentation of the change in risk resulting from initiation of options either singly or
in combination, and encouragement to consider their values and make a decision. Like most
decision aids, the Heart to Heart decision aid helps patients implicitly consider their values
(see Figure 2) by providing information about the pros and cons of various risk reducing
options (including their risk reduction singly or in combination). It additionally prompts
individuals to make a decision.
The explicit values clarification exercise that we added to the Heart to Heart decision aid for
participants in our second intervention arm was a ranking and rating exercise. We chose a
ranking and rating exercise because ranking and rating are simple, familiar tasks with results
that can be summarized and reflected back to individuals to allow additional consideration
of values. Values in our ranking and rating exercise were decisional attributes common to
each of the treatment options presented in the decision aid (benefit for other medical
conditions, side effects, degree of difficulty for most people, cost, and effect on others).
These attributes were a subset of decisional attributes identified as relevant to participants in
formative research9 and were chosen for their differences across treatment options.
During the values clarification exercise (see Figure 3), participants first ranked the
decisional attributes according to their individual importance to their decision making. They
then rated whether each attribute related to their personal decision options; rating proceeded
in the order of the previously ranked decisional attributes. At the end of the exercise,
participants viewed a summary table of their answers allowing additional consideration of
their values.
Delivery of the Surveys and Interventions
At the beginning of the study session, all participants completed a baseline questionnaire to
assess their demographic information, attitudes toward heart disease prevention, decisional
conflict, and intent to reduce their CHD risk. They were then randomized to the DA or DA +
VC arms. Participants in both groups viewed the decision aid, entering risk factor
information and navigating interactively through decision aid content. All participants were
then asked to make a choice among treatment options, including the option of doing nothing,
to lower their risk of heart disease. Participants in the DA + VC arm then worked through
the ranking and rating values clarification exercise and again indicated their choice for
lowering their CHD risk. All participants completed a final questionnaire assessing their
decisional conflict, intent to reduce their CHD risk, their self-efficacy for risk reduction, and
their perception that they made a decision consistent with their values. All participants
received $25 for their participation.
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Decision Making Outcome Measures
The primary outcome for our study was decisional conflict. We additionally measured
several other secondary outcomes: intent for CHD risk reduction, perceived values
concordance, and self-efficacy for risk reduction. Finally, we measured three post-hoc
outcomes: intent for specific treatments post-intervention; changes in intent for specific
treatments post (compared with pre) intervention; and total number of treatments intended
after the intervention.
We measured decisional conflict at baseline and post-intervention using the Decisional
Conflict Scale, a well-validated 16-item scale examining several features of conflicted
decision making, including feeling uncertain, uninformed, unclear about one’s values,
unsupported, or ineffective in making choices.12,13 The Decisional Conflict Scale
discriminates well among persons who plan to immediately make and implement a decision
and those who will delay both decision-making and action (alpha 0.81, test-retest reliability
0.81). The 3-item values subscale has been widely used by experts to measure the effect of
decision aids on values and includes the following questions: 1) “I am clear which benefits
matter most to me,” 2) “I am clear about which risks and side effects matter most to me,”
and 3) “I am clear about which is most important to me (the benefits or the risks/side
effects). For both the full Decisional Conflict Scale and the values subscale, we summed and
averaged responses. Scores range from 1 to 5 with scores less than 2 indicating intent to
immediately make and implement a decision.
We used a single question at baseline and post-intervention (and additionally between the
DA and VC components in the DA + VC group) to assess participants’ intent to change
behavior: “Are you planning to lower your chances of heart disease?” We counted a yes
answer to this question as intent to lower CHD risk.
We measured participants’ perceived values concordance (i.e. their perception that their
decision was consistent with their values) post-intervention by agreement with a single
statement: “My decision was consistent with my personal values.” Participants provided
answers on a 5-point Likert scale dichotomized to strongly agree/agree versus all others.
We assessed self-efficacy for risk reduction at baseline and post-intervention with the single
statement, “I am confident that I can carry out my plan to lower my chances of heart
disease.” Again, participants provided answers on a 5-point Likert scale with answers
dichotomized to strongly agree/agree versus others.
We measured intent for specific treatments using a follow-up question to our general intent
question listed above. All participants who agreed that they intended to lower their CHD risk
checked boxes indicating their intended method(s) for lowering their CHD risk among a list
of 6 possible methods (aspirin, blood pressure medicine, cholesterol medicine, smoking
cessation, diet, and exercise), four of which were the focus of our intervention because of
they are supported by evidence of the highest design and quality.
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Because the addition of a values clarification exercise might affect tool use and patients’
understanding and use of other information provided in the decision aid, we measured
several process measures. These included total time spent with the tool (measured
electronically by the computer), and agreement with simple declarative statements that Heart
to Heart was easy to use, easy to understand, helped personalize information, and helped
decide what was important. For those in the DA+VC arm, we also asked how easy the
processes of ranking and rating were, whether they used the summary table to make a
decision, and whether the summary table showed how they felt.
Statistical Analysis
To assess the success of randomization, we compared the baseline characteristics of subjects
who received the DA with those who received the DA + VC. To assess the effects of the
explicit values clarification intervention, we then compared DA and DA + VC groups with
respect to our primary outcome, post-intervention decisional conflict, using both t-tests and
Wilcoxon rank-sums. Because these tests produced similar results, we report t-tests and
present means and confidence intervals for ease of interpretation. We assessed the effect of
the explicit values clarification intervention on our secondary outcomes (intent to be
screened, perceived values concordance, and self-efficacy for CHD risk reduction) using
Pearson’s chi square tests. We then compared DA and DA + VC groups with respect to post-
intervention intent for specific treatment and post-intervention changes (compared to
baseline) in intent for specific treatment, using Pearson chi square tests. We additionally
performed regression analyses (linear regression for continuous outcomes and logistic
regression for dichotomous outcomes) to compare study arms with respect to our primary
and some secondary outcomes, after adjusting for small (but potentially meaningful)
differences in baseline values. Finally, we compared the number of intended treatments post
intervention using the Cochrane-Armitage Trend Test. Wherever possible, we report
absolute differences with 95% confidence intervals to allow estimation of both the effect
size and the precision of our results. All analyses were conducted using SAS 9.2 Statistical
Software (Cary, NC).
Sample Size Calculation
We calculated a sample size to detect a mean difference of 0.40 in the decisional conflict
scale. We chose this difference because we felt it would be clinically meaningful and
because it would be consistent with the difference in the decisional conflict scale and its
values subscale between those who received decision support and those who didn’t in
previous decision aid studies for preventive interventions.12 Using this difference, a DA
decisional conflict score of 2.0 for the control group (which we estimated from our pilot
work and existing literature14), a standard deviation of 0.6, a two-sided alpha of 0.025, and a
power of 90%, we calculated a sample size of 64 in each group (128 total) to detect a 0.4
point difference, using a Wilcoxon Rank-Sum test. A sample size of 128 would allow us
approximately 80% power to detect a 14% or greater difference in secondary dichotomous
outcomes (intent to reduce CHD risk, perceived values concordance, and self efficacy for
risk reduction).
Sheridan et al. Page 6






















When a study of a CHD prevention decision aid15 came to our attention during the study
period, we recalculated a sample size using decisional conflict parameters from that study
(baseline decisional conflict 2.3, average difference in decisional conflict pre-post decision
aid 0.3) and found a similar sample size. Thus, we continued recruitment as planned.
Results
We contacted 296 decision registry participants about participation in our study (see Figure
4). 174 responded with interest. Of those, 160 were eligible. Seven refused participation, 2
could not be scheduled for a research session, and 11 who were scheduled did not present
for their session. 140 individuals were randomized (65 to the DA group and 75 to the DA +
VC group) and 137 ultimately completed the study.
Participant characteristics are shown in Table 1. Mean age was 52 and 78% were female.
Most were white, had at least some college education, and favored shared or patient-led
decision making. Using a combination of personal and study provided risk factor
information, most had a 10-year risk of CHD events of 10%. There were no appreciable
baseline differences by study assignment.
The Effect of the Intervention on Primary and Secondary Outcomes
Adding a ranking and rating exercise to a decision aid on heart disease prevention had no
apparent effect on our primary outcomes in this study (see Table 2). Although both of our
interventions reduced decisional conflict (DA −0.6; DA + VC −0.6), we found no clinically
or statistically significant differences between groups in decisional conflict post-intervention
(DA 1.8; DA+VC 1.9; absolute difference VC-DA 0.1, 95% CI −0.1 to 0.3; adjusted
difference −0.01, p 0.95). Intent to reduce CHD risk was high at baseline and did not differ
by group post intervention (DA 98%; DA+VC 100%; absolute differences VC-DA: 2%,
95% CI −0.02% to 5%). Additionally, a majority of individuals in both the DA and DA+VC
groups reported decisions consistent with their values post-intervention (DA 95%; DA+VC
92%; absolute difference −3%, 95% CI −11% to +5%) and self-efficacy was similar
between groups post-intervention (DA 97%; DA+VC 92%; absolute difference VC-DA:
−5%, 95% CI −13 to +3%).
The Effect of the Decision Aid on Post-Hoc Outcomes
Tables 3 shows the proportion of individuals intending to start specific risk reducing
treatments at various points in time. There were no significant differences in the proportion
of individuals planning to start specific risk reducing treatments post intervention (post-DA
in the DA group and post-VC in the DA+VC group). Table 4, however, shows that there was
a trend toward more participants in the DA+VC group changing their decisions about
cholesterol (absolute difference +7%, 95% CI −5% to +21%) and blood pressure
medications (absolute difference +9%, 95% CI −3 to +21%). There were no apparent
differences between groups in the proportion of participants changing decisions about other
CHD risk factors. There were also no differences in the proportion of individuals planning
various numbers of treatments post-intervention (p 0.56 for trend).
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The Effect of the Interventions on Process Measures
The addition of a ranking and rating exercise to a decision aid on heart disease prevention
increased the mean number of minutes spent with the tool from 5 minutes (range 1 to 12
minutes) to 11 minutes (range 4 to 21 minutes). It did not, however, increase participants’
perceptions that the tool helped decide what was important (DA 87%; DA + VC 75%). A
majority of participants in the DA+VC group reported the ranking and rating was easy to do
(76% and 80% respectively) and the summary table showed how they felt (78%), however,
only 62% reported they used the summary table to make a decision. Importantly, the ranking
and rating exercise did not change participants’ perceptions that the decision aid was easy to
use (DA 100%; DA+VC 95%), easy to understand (DA 97%; DA+VC 95%), personalized
information for them (DA 95%; DA+VC 96%).
Discussion
In a hypothetical lab-based study, adding a ranking and rating exercise to a heart disease
prevention decision aid did not improve participants’ decisional conflict, intent to reduce
their CHD risk, sense of values concordance, or self-efficacy for risk reduction. It also did
not improve process measures for the decision. Both our DA and our DA + VC interventions
reduced decisional conflict and resulted in perceptions of decisions consistent with personal
values and self-efficacy for CHD risk reduction. Neither had an effect on intent to reduce
CHD risk, which was high at baseline and remained essentially unchanged in this study.
These findings raise questions about the additional benefits of an explicit values clarification
exercise as part of a decision aid (compared with implicit consideration of values), but by no
means provide a definitive answer. Explicit values clarification exercises come in many
forms and relatively few have been tested as adjuncts to decision aids. 4,6,16–19 Additionally,
ranking and rating exercises, such as the one in this study, may be conceptualized in several
ways that might affect their efficacy. Inclusion of additional or different decisional
attributes, a different process for ranking and rating, or a different summary of the values
clarification exercise might have produced different results.
Measurement of different outcomes might additionally affect conclusions. We chose the
decisional conflict scale as our primary outcome because it is widely used and its values
subscale directly measures an individuals clarity about which benefits, risks, and side effects
of a decision matter most, and which are more important (the benefits or the risks and side
effects). Using this scale, the baseline decisional conflict in our study was moderate (DA
2.4; DA +VC 2.5) and, when converted to the newer 0–100 scale (by subtracting 1 and
multiplying by 25: DA 35; DA + VC 37.5), similar to the decisional conflict reported in the
usual care group of many other decision aid studies on topics ranging from surgery for
ischemic heart disease to colorectal cancer screening.4 Using this scale, we showed
improvements (−0.6 units on a 1–5 scale; −14 on a 0–100 scale) in both the DA and DA+
VC arms, which exceed the mean difference in decisional conflict (−6.12, 95% CI −8.62 to
−3.63 on a 0–100 scale) in randomized studies comparing the effects of decision aids and
usual care.4 We, however, found no differences between intervention arms. It is unclear
whether this lack of effect is because there really is no difference in decisional conflict,
because the decisional conflict scale can’t be meaningfully lowered more than we did by our
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decision aid alone (i.e. there is a floor effect), or because the decisional conflict scale itself is
insufficient to capture the differential benefits of an explicit values clarification exercise (i.e.
values clarification involves tradeoffs other than those among benefits, risks, and side
effects; e.g. cost, level of difficulty). These latter possibilities are empiric questions. Some
existing evidence argues against a floor effect for the decisional conflict scale because
studies of decision aids for breast cancer treatment, anti-thrombotic therapy for atrial
fibrillation, and blood transfusion prior to heart surgery have achieved appreciably lower
decisional conflict scores (ranging from 10 to 17 on a 0–100 scale) than the post-
intervention decisional conflict scores in our study (DA 21; DA +VC 22.8 on a 0–100
scale).4 It is possible, however, that the achievable decisional conflict may be different for
CHD prevention decisions and more testing is necessary. The ability of the values subscale
of the decisional conflict scale to capture relevant values could be tested simply through
cognitive interviewing. Until such issues are resolved, other outcomes should also be
explored to measure the benefit of explicit values clarification.
What outcome might best capture the effects of an explicit values clarification exercises is
unclear. In our study, we attempted to explore several outcomes we felt might be potentially
useful: the perception that decisions are consistent with personal values, self-efficacy to
carry through on one’s decision, and intent to adhere to one’s chosen decision.
Unfortunately, we were limited by ceiling effects (probably due to use of a hypothetical
scenario and our choice of study population) and these outcomes will need to be examined
further in future studies. Outcomes proposed (or used) by other decision aid researchers (e.g.
the variance in behavioral intent explained by values, and the percentage agreement or
correlation between values and behavioral intent)4,16,20,21 should also be further explored;
however, care must be taken to ensure that all relevant values are accounted for.
Whatever values clarification exercise or measure is employed, future studies of explicit
values clarification exercises should learn from the limitations of our work. First, we
recruited a non-clinical population and used hypothetical scenarios to ensure our decision-
makers had adequate CHD risk and, thus, adequate opportunity for tradeoffs among CHD
risk reducing options. This may have produced limited investment in the decision making
task and have artificially elevated self-efficacy. Studying actual clinical populations making
CHD prevention decisions would provide more realistic estimations of the benefit of explicit
values clarification exercises for such a decision. Second, we recruited our population from
a decision aid registry. While this allowed for ease of recruitment, it meant that we sampled
a highly educated and motivated population and encountered ceiling effects for some of our
outcomes of interest (e.g. intent to reduce CHD risk and self-efficacy). Studying a more
diverse population (by recruiting a clinical population or oversampling individuals with
lower motivation and self-efficacy) would provide a better opportunity to define the effects
of explicit values clarification exercises. Finally, our sample size was too small to test for
interactions in intervention effect. It is possible that the efficacy of values clarification
exercise varies by characteristics such as literacy level and familiarity with decisions, thus,
future work should plan for larger sample sizes and subgroup analyses to explore this
possibility.
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Limitations aside, we feel our study raises important questions for values clarification
research. Future studies should explore different values clarification exercises and different
outcomes in more diverse populations.
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Implicit Values Clarification Embedded within Heart to Heart Decision Aid
Figure 2a. Calculations of Risk Reductions Possible by Intervening with Various Combinations of Treatment
Figure 2b. Summary of Treatment Options and their Pros/Cons
Figure 2c. Encouragement to Consider Values and Make a Decision
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Overview of Explicit Values Clarification Exercise Added to Heart to Heart Decision Aid
Figure 3a. Ranking of Importance of Factors Related to Decision.
Figure 3b. Rating Relevance of Decision Factor for Personally Relevant Treatment Options*
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* Rating proceeded in the order of importance of previously ranked decision factors.
Figure 3c. Summary of Participant’s Responses to Ranking and Rating Exercise
* The more hearts to the left or the more in a row, the more favorable the option.
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Table 1
Participant Characteristics (n=137)
Characteristic DA DA + VC
Mean age 52.4 52.5
Female (%) 74% 81%
Race:
 White (%) 79% 77%
 Black (%) 21% 17%
Education:
 At least some college (%) 93% 95%
Smoking (%) 11% 8%
Diabetes (%) 8% 5%
Accurate perception of CHD risk* (%) 25% 32%
Knowledgeable about the best options for CHD risk reduction† (%) 77% 79%
Preferred participation in decision making about CHD (%):
 I decide 2% 11%
 Share decision 96% 85%
 MD decide 2% 4%
Decisional Conflict (mean)‡:
 Overall 2.4 2.5
 Values subscale 2.5 2.6
Intent to reduce CHD risk (%)
 Any plan 97% 97%
 Best plan† 68% 60%
*
Estimation requires consideration of both personal and hypothetical information contributing to CHD risk
†
Includes best evidence plans promoted by our decision aid, including hypertension med, cholesterol med, smoking cessation, and aspirin.
‡
 Reported on 1–5 scale; to convert to 0–100 scale, subtract 1 and multiply by 25.
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Table 2
The Effect of Values Clarification on the Decision: Differences in Post-Decision Aid Outcomes by Study
Group




 Overall 1.8 1.9 +0.1 (−0.1, +0.3) −0.01, p= 0.95
 Values subscale 1.8 1.9 +1.8 (−0.2 to +0.4) −0.04, p= 0.73
Secondary Outcomes
Intent to reduce CHD risk
 Any plan 98% 100% +2% (−0.02% to +5%) --
 Best plan† 71% 65% −6% (−10% to 21%) ‡, p=0.82
Decision c/w with values 95% 92% −3% (−11% to +5%) --
Self-efficacy to lower at least one CHD risk
factor 97% 92% −5% (−13% to +3%) --
*
reported on 1–5 scale; to convert to 0–100 scale, subtract 1 and multiply by 25.
†
 Includes best evidence plans promoted by our decision aid, including hypertension med, cholesterol med, smoking cessation, and aspirin.
‡
adjusted absolute difference can not be estimated for categorical variables
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Table 4
Proportion of Participants Changing Intent For Specific Treatment After the Intervention
Changed Intent DA (n=62) DA + VC (n=75) Absolute Difference (95% CI)
% changing intent about:
Smoking, if a smoker (n=19) 9% 38% +29% (−9% to +66%)
BP medication (n=137) 11% 20% +9% (−3% to +21%)
Cholesterol medication (n=137) 16% 24% +7% (−5% to +21%)
Aspirin, if can take aspirin (n=125) 27% 22% −5% (−20% to +10%)
Any change 90% 94% +4% (−4% to +13%)
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